Trials / Terminated
TerminatedNCT00638131
Bosentan Use in Patients With Diabetic Nephropathy
Effect of Bosentan on Systemic and Renal Inflammatory Markers in Patients With Diabetic Nephropathy on Angiotensin II Receptor Blockers
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM) · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
There is little doubt of the necessity for further improvement in the prevention and therapy of end-stage renal disease. Despite the success of ARB in treating diabetic nephropathy, not all patients obtain satisfactory control of blood pressure, albuminuria and decline in renal function. Experimental data have provided us with a rationale for the potential added benefits of ET receptor blockade to the AII inhibition in diabetic renal protection. Considering the nephroprotective effect of bosentan in diabetic rats, clinical studies are warranted to assess whether ET receptor antagonism has additive renoprotective effects on top of AII inhibition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bosentan | 62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2010-03-01
- Completion
- 2010-06-01
- First posted
- 2008-03-18
- Last updated
- 2020-07-24
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00638131. Inclusion in this directory is not an endorsement.